The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
263
Daily topical application
Daily topical application
Unnamed facility
Anaheim, California, United States
Unnamed facility
Honolulu, Hawaii, United States
Unnamed facility
Boise, Idaho, United States
Eczema Area and Severity Index (EASI)
Eczema area and severity index
Time frame: At baseline
EASI
Ezcema area and severity index
Time frame: Measured after one week of treatment
EASI
Eczema area and severity index
Time frame: Measured at the end of 2 weeks of treatment
EASI
Eczema area and severity index
Time frame: Measured at the end of 3 weeks of treatment
EASI
Eczema area and severity index
Time frame: Measured at the end of 4 weeks of treatment
Subjects' assessment of pruritus
Subjective measurement on a point scale
Time frame: Measured at baseline
Subject's assessment of pruritus
Subjective measurement on a point scale
Time frame: Measured after one week of treatment
Subject's assessment of pruritus
Subjective measurement on a point scale
Time frame: Measured after two weeks of treatment
Subject's assessment of pruritus
Subjective measurement on a point scale
Time frame: Measured after three weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Chicago, Illinois, United States
Unnamed facility
Boston, Massachusetts, United States
Unnamed facility
Warren, Michigan, United States
Unnamed facility
Fridley, Minnesota, United States
Unnamed facility
New York, New York, United States
Unnamed facility
Portland, Oregon, United States
Unnamed facility
Austin, Texas, United States
...and 6 more locations
Subject's assessment of pruritus
Subjective measurement on a point scale
Time frame: Measured after four weeks of treatment